Kolexia
Ducray Francois
Neurologie
Hôpital Pierre Wertheimer
Bron, France
323 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du cerveau Gliome Glioblastome Oligodendrogliome Encéphalite Astrocytome Récidive tumorale locale Délétion de segment de chromosome Lymphomes

Industries

Servier
5 collaboration(s)
Dernière en 2023
NOVOCURE FRANCE SAS
4 collaboration(s)
Dernière en 2023
STETHOS
1 collaboration(s)
Dernière en 2022
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Essai Clinique (Biohaven Pharmaceuticals, Inc.)   21 mars 2024
POLO: A Randomized Trial of Delayed Radiotherapy in Patients 1p/19q Codeleted Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
Essai Clinique (Hospices Civils de Lyon)   15 mars 2024
Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial.
Nature communications   23 février 2024
SONOBIRD: A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma.
Essai Clinique (CarThera)   30 janvier 2024
GLIOLI: Biological Collection of Brain Tumors - GLIOLI Collection
Essai Clinique (Hospices Civils de Lyon)   25 janvier 2024
Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide.
Minerva endocrinology   19 janvier 2024
Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
European journal of cancer (Oxford, England : 1990)   18 décembre 2023
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO): A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Essai Clinique (Servier)   01 décembre 2023
Classification moléculaire de 83 glioblastomes cérébelleux français et identification de sous-groupes pronostiques
Congrès AM/CHEC 2023   01 décembre 2023
A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules.
Pharmaceutics   24 novembre 2023